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described. Umbilical cord blood (UCB) transplantation is an
alternative donor source that has been reported to have lower
risks of CGVHD compared to matched related donor (MRD)
and unrelated donor transplantation. We conducted a single cen-
ter retrospective analysis to describe resource utilization associ-
ated with CGVHD. We also compared resources used by
recipients of UCB and MRD HCT. We assembled a cohort of
adult patients ($ 18 years) who received an allogeneic HCT at
our center from 2005-2007, had survived for at least 100 days
post-transplant and had a diagnosis of CGVHD. From the 83 pa-
tients (MRD 42. UCB 41) who met our criteria, we limited our
study to patients who had received all their care at our center
through 2 years post-HCT, relapse or death, which ever occurred
earlier. Our final cohort included 51 patients (MRD 29, UCB 22).
For both donor sources, included and excluded patients had com-
parable NIH severity, type and onset of CGVHD. For compari-
son purposes, we randomly selected a group of 45 controls who
met the same criteria as cases but had no CGVHD. Controls
were matched to cases by donor source and duration of followup
after HCT. For MRD and UCB recipients, median time to onset
of CGVHD was 175 and 144 days (P 5 0.73) and 55% and 59%
presented with overlap syndrome (P 5 0.78), respectively. Over-
all, 7%, 72% & 21% MRD and 27%, 65% & 5% UCB had
NIH graded mild, moderate and severe CGVHD (P 5 0.06).
Table 1 shows utilization of various resources among patients
with CGVHD and controls. There were similar patterns of re-
source utilization with respect to number of outpatient visits, hos-
pitalizations, and duration of hospital stay among UCB and MRD
recipients with CGVHD. However, a larger number of UCB re-
cipients with CGVHD were excluded because of receipt of care
elsewhere. Patients with chronic GVHD utilize extensive health
system resources. More research is needed to better understand
the costs of CGVHD to patients, centers and the health care
system and to determine if the lower incidence and severity of
CGVHD with UCB leads to long-term resource savings com-
pared to other graft sources.537
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Shwachman Diamond Syndrome (SDS) is a rare autosomal reces-
sive disorder with a varied clinical presentation of developmental,
metabolic and hematopoetic defects. Bone marrow transplantation
(BMT) is an accepted therapy to correct the potentially fatal compli-
cations of bone marrow failure, granulocytopenia and thrombocyto-
penia that are associated with SDS.
The subject of this report is a 10 year old girl diagnosed with SDS.
After a prolonged history of life-threatening infections and throm-
bocytopenia, BMT was pursued. Following myeloablative therapy,
the patient received a BMT from a 9/10 matched unrelated donor
(MUD). Complete engraftment was noted at two weeks by short tan-
dem repeat (STR) analysis of the mononuclear cells (MNC) and
granulocytes. The clinical course over the next year was complicated
by multi-organ graft versus host disease (GVHD) requiring liver
transplantation from a living related donor.Within 6months the pa-
tient was re-hospitalized with recurrent GVHD. STR analysis iden-
tified the presence of MNC derived from the solid organ transplant.
Regular monitoring of the engraftment by STR revealed that the
solid organ transplant-derived cells rapidly and selectively reconsti-
tuted the T cell compartment of the peripheral blood. Surprisingly,
the granulocyte and B cells were derived from the HSC donor. Fol-
lowing a complicated course of bone marrow aplasia, thrombocyto-
penia, sepsis and renal insufficiency the patient succumbed to
GVHD.
GVHD following solid organ transplantation is relatively uncom-
mon; however, the effects can be devastating. Here we present a casewhere passenger T cells from a solid organ transplant elicited
GVHD. These results demonstrate that the solid organ-derived T
cells were able to mount an effective immune response against the
patient and the HSC donor resulting in renal failure and bone
marrow aplasia, respectively. These results highlight the necessity
of determining compatibility between all cell and tissue types in-
volved in complex transplantation procedures.538
RETROSPECTIVE, SINGLE CENTER STUDY OF SMART PORT CT
IMPLANTED CATHETERS (VORTEX PORT) FOR POST TRANSPLANT
EXTRACORPOREAL PHOTOPHERESIS FOR TREATMENT OF STEROID
REFRACTORY GRAFT-VS-HOST DISEASE
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Graft versus host disease (GVHD) is a major cause of morbidity
and mortality after allogeneic hematopoietic cell transplant
(HCT). Extracorporeal photopheresis (ECP) has been used success-
fully in the treatment of steroid refractory GVHD. Our center first
used ECP for GVHD in 1999. Our protocol for treatment of cuta-
neous GVHD is ECP two days per week every other week for three
months then reevaluate. If GVHD is improving, the frequency of
treatment would be reduced to two days per month. For visceral
GVHD, ECP treatment would be given three days per week every
other week for three months and then reassess and taper as above.
We currently use vortex ports (AngioDynamics, Latham, NY) for
long term access in our HCT patients and we hypothesize that it is
possible to perform ECP using vortex ports in patients with steroid
refractory GVHD and that the use of the port instead of external
catheters or venopuncture will improve quality of life for these
patients.
Patients who received at least one ECP treatment for treatment of
steroid refractory GVHD at our center between 1/1/07 and 9/30/10
were included (n5 47). During that time our center performed 1632
ECP procedures for treatment of GVHD including 552 procedures
after vortex port placement in 19 patients. Fifteen patients completed
100% of their ECP procedures with the vortex port after it was
placed. These patients had a total of 400 procedures with a range
of 6-51 procedures and a mean of 26.7 per patient. Four patients
had some of their procedures done with the port but required an-
other access method for 19 procedures. These patients had a total
of 133 procedures with a range of 27-36 and a mean 33.25 per pa-
tient. Of the patients that did not use the vortex port 100% of the
time, one had an uncomplicated line infection, one preferred IV ac-
cess to port use, one had anatomic issues with port placement, and
one had access to the port impaired by scleroderma. Overall, 97%
(533/552) of ECP procedures performed in patients with a vortex
port were completed using the port. Therefore, we conclude that
the use of the vortex port for ECP patients with steroid refractory
GVHD is feasible. Future studies are needed to evaluate infection
rate, bleeding risk, and quality of life in these patients compared
with those receiving ECP with external catheters or venopuncture
particularly in patients with sclerodermatous cutaneous GVHD.539
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WITH INCREASED RISK FOR ACUTE GRAFT-VERSUS-HOST DISEASE
Ram, R.1, Paul, M.2, Gafter-Gvili, A.1, Hershkovitz, K.1, Israeli, M.1,
Peck, A.1, Raanani, P.1, Shpilberg, O.1, Yeshurun, M.1 1Rabin Medical
Center and Sackler School of Medicine, Tel Aviv University, Petah-Tikva,
Israel; 2Rabin Medical Center and Sackler School of Medicine,, Petah-
Tikva, Israel
Acute graft-versus-host disease (aGVHD) has remained a signifi-
cant cause of non-relapse mortality after allogeneic hematopoietic
cell transplantation (HCT). The conditions favoring the develop-
ment of aGVHD are thought to occur in the earliest phases of
Table 1. Early febrile and documented infectious episodes among 54 HCT patients.
Febrile episodes DIE CDI MDI Bacteremia IFI
N episodes in all patients 24 14 1 4 10 0
Incidence per 100 patients (n5 54) 44 26 2 7 19 0
Incidence per 1000 neutropenia
days (n5737)
32 19 1 5 14 0
Specific presentation or pathogen N/A N/A Pneumonia Influenza A (n51),
CMV (n51), Clostridium
difficile (n51), Coagulase
negative staphylococci
Escherichia coli (n55), Stenotrophomonas
maltophilia (n51), Coagulase negative
staphylococci (n51), Staphylococcus
aurus (n51), Streptococcus pneumonia
(n51), Enterococcus (n51)
N/A
DIE – documented infectious episodes, CDI – clinical documented infections, MDI – microbiology documented infections, IFI – invasive fungal infections,
N/A – not applicable.
Poster Session II S347HCT. We hypothesized that early febrile or documented infectious
episodes (from day 0 through engraftment) would promote the de-
velopment of aGVHD. Data regarding febrile episodes (defined as
clinically and/or microbiologically documented infections or epi-
sodes with fever . 380C for two consecutive days to exclude drug
and blood-product-related fever) were prospectively collected for
patients undergoing HCT. In addition, all patients’ charts were ret-
rospectively reviewed for the onset, staging/grading of aGVHD and
for patient-donor characteristics. 54 consecutive patients undergo-
ing HCT were included. Median patient age was 51 (range, 22-67)
years. Preparative regimen was myeloablative (MA) (n 5 23) or re-
duced intensity (n 5 31) conditioning. 27 pts received peripheral
blood stem cells (PBSC) fromHLA-identical siblings, 25 patients re-
ceived PBSC from unrelated donors (19 HLA-matched PBSC and 6
received 1-HLA-Agmismatched PBSC) and 2 patients received dou-
ble umbilical cord blood graft. Post-grafting immunosuppression
consisted of combined cyclosporine with either methotrexate or my-
cophenolate mofetil. Patients receiving an unrelated donor graft
were also given ATG. By day 120, 34 pts (63%) developed grade
2-4 aGVHD. 24 pts developed febrile episode, 14 of whom had
documented infectious episodes (clinical documented infection,
n 5 1; microbiology documented infection, n 5 3 and bacteremia,
n 5 10).Patients who developed a febrile episode had a higher risk
for developing grade 2-4 (OR 5 5.7, 95% CI 1.6-20.8, p\ 0.05)
and grade 3-4 (OR 5 3, 95% CI 0.8-10.6, p 5 0.08) aGVHD.
Among other risk factors for aGVHD (MA conditioning, female do-
nor to male recipient, unrelated donor and 1-HLA-Ag mismatched
graft), only MA conditioning was associated with an increased risk
for aGVHD with borderline statistical significance (OR 5 2.8,
95%CI 0.8-9.5, p5 0.09).We conclude that febrile episodes occur-
ring early, before engraftment, are associated with higher risk for
GVHD. Confirmation of these findings in larger cohorts is war-
ranted. The types of infections possibly promoting aGVHD should
be defined.540
ETANERCEPT FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST
DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Park, J.S., Jeong, S.H., Ahn, M.S. Ajou University School of Medicine,
Suwon, Kyunggi-do, Korea
Treatment strategy for steroid-refractory acute graft-versus-host
disease (GvHD) after allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) needs to be standardized.We report our clinical
experience of the effect of etanercept on steroid-refractory acute
GvHD. A total of 18 consecutive patients with steroid-refractory
acute GvHD were retrospectively studied. Twenty-five milligrams
of etanercept were given subcutaneously twice weekly for four weeks.
Clinical responses were evaluated with regard to the severity of acute
GvHD. The median age of patients was 43.5 years. Before etaner-
cept, grade IV, grade III, grade II, and grade I acute GvHDoccurred
in seven, six, five, and zero patients, respectively; however the num-
ber of patients changed to four, five, five, and four, respectively, afteretanercept (p.005). Eighty percent of grade II, 14% of grade III, and
57% of grade IV patients showed a partial response. Skin and gut
GvHD were well controlled with etanercept, whereas hepatic
GvHD was not. Three patients died of fatal infection. There were
no factors affecting the clinical outcome of etanercept. All the
non-responders died and 56.6% of the responders survived
(p0.0008). Etanercept can be effective in treating steroid-refractory
acute GvHD after allo-HSCT, with tolerable side effects.541
THE ROLE OF PLASMA CYTOKINES IN THE DIAGNOSIS OF AUTOIMMUNE
PHENOMENA IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
UNDERGOING NOVEL ANTI-MYELOMA THERAPIES AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT)
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Rhee, F., Anaissie, E. University of Arkansas for Medical Sciences, Little
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Introduction: Auto-immune (AI) phenomena among MM patients
receiving novel agents and auto-HCT usually present with fever,
skin rash and include a transient engraftment syndrome (ES) or
more serious complications, Graft vs. Host Disease (GvHD) and
DRESS (drug rash with eosinophilia and systemic syndrome) with
the latter two requiring specific therapies.The clinical characteristics
of these 3 syndromes may overlap, complicating patient manage-
ment. We evaluated a set of clinical and laboratory diagnostic crite-
ria, including a plasma cytokine (PC) panel, to help diagnose these
clinical syndromes.
Patients andMethods: A retrospective review of medical records of
MMpatients (pts) who developed a skin rash between 2007 and 2010
and on whom PC panels were obtained. Clinical findings including
fever, skin rash, results of skin biopsies (SBx), clinical recurrence of
symptoms during tapering of therapy were evaluated. Laboratory
values evaluated included eosinophilia, liver and renal function tests,
plasma cytokines levels {soluble interleukin -2 (IL-2) receptor,
IL-4,5,6,8,10, IFN g, TNF-a, Eotaxin-3 and Eosinophil derived
neurotoxin (EDN)}. The mean, median and range of lab results
were calculated.
Results: pts were categorized into 4 groups: DRESS (n 5 25),
GVHD (n 5 6), ES (n 5 4), simultaneous DRESS and GVHD
(n5 1) and controls (29 pts without AI phenomena). The incidence
of eosinophilia and liver dysfunctionwere significantly higher among
pts with DRESS vs. those with GvHD, ES and controls. SBx results
differed between pts with DRESS (spongiosis and/or increased eo-
sinophils, 95% of pts) and those with GvHD (67% had any 2 of
the following: interface dermatitis, baso-vacuolation or peri-vascular
lymphocyte infiltration). The mean of PC, characteristics of eosino-
phil involvement were significantly elevated among pts with DRESS
compared with GVHD, ES or controls including higher values for
IL-5 (31.9 pg/mL in DRESS vs. 4 pg/mL in control), eotaxin-3
(24.5 pg/mL vs. 13.3 pg/mL) and EDN (98.8ng/mL vs. 17.5ng/
mL). Recurrence of events was noted among 7 of 25 pts with DRESS
vs. 1 of 6 and none of 4 among those with GVHD and ES, respec-
tively.
